Fig. 2From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsEffect of MRF on OS of patients with a AML30+, b AML20–30 and c AML (all patients)Back to article page